

526 Rec'd PCT/PTO 16 JUL 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inve Application of  
**HERSCOVICI ET AL.**

Examiner: UNASSIGNED

Art Unit: UNASSIGNED

Serial No.: 09/857,008

September 12, 1999

Title: **Novel Nucleic Acid Transferring Agents,  
Compositions Containing them and Uses**

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
~~first class~~ ~~registered~~ mail in an envelope addressed to  
Commissioner for Patents, Washington, D.C. 20231, on

Date of Deposit 7-13-2001

Signature *Robert J. Inman*

~~Express Mail No.~~

RESUBMISSION OF SEQUENCE LISTING AND STATEMENT UNDER 37 CFR 1.821

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants' attorney recently received a telephone call from the USPTO, wherein the USPTO employee asserted Applicants had not supplied a sequence listing with the filing of this Application. Applicants did provide such documents when the instant Application was filed. However, in order to expedite prosecution of the instant Application, Applicants resubmit the sequence listing (both hard copy and in electronic form), and the Statement.

Respectfully submitted,

*William C. Coppola*  
William C. Coppola, Reg. No. 41,686  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-4854  
Telefax (908) 231-2626

Docket No. ST98046-PCT-US

1. *Phragmites* (common)